PDF-How to Comply with the Pediatric DRAFT GUIDANCE This guidance document PDF document

Additional copies are available from Office of Training and Communications Division of Drug Information HFD240 Center for Drug Evaluation and Research CDER Food

Upload by celsa-spraggs
Published on 2016-05-06

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/308482" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "How to Comply with the Pediatric DRAFT G..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

How to Comply with the Pediatric DRAFT GUIDANCE This guidance document: Transcript

PDF-How to Comply with the Pediatric DRAFT GUIDANCE This guidance document PDF document

Presentation Embed Code

Download Presentation

How to Comply with the Pediatric DRAFT GUIDANCE This guidance document: Transcript

Related Contents

Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance

Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment

Guidance for Industry and FDA Staff Submissions for Postapproval Modifications to a Combination

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE

Guidance for Industry Contract Manufacturing Arrangements for Drugs Quality Agreements

Informed Consent Information Sheet Guidance for IRBs Clinical Investigators and Sponsors

Guidance for Industry Distributing Scientific and Medical Publications on Unapproved New

Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of

Guidance for Industry Safety Considerations for Container Labels and Carton Labeling

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits

Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE

Guidance for Industry Interim Product Reporting for Human Drug Compounding Outsourcing